Fortress Biotech repays USD 15 million debt: what it means for Fortress Biotech stock

Published on 10/14/2026 at 06:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fortress Biotech repaid USD 15.00 million of debt on September 30, 2026. Fortress Biotech stock sits at a USD 64.8 million market value.

Capital structure and reporting schedule

Fortress Biotech repaid USD 15.00 million of Oaktree principal on September 30, 2026.
Second-quarter revenue reached USD 18.72 million after a 7.20 percent consensus beat.
The next earnings report is scheduled for November 12, 2026.

FBIO, US34960Q3074, Illustration mit AI erstellt.

Fortress Biotech (ISIN US34960Q3074) repaid USD 15.00 million of remaining Oaktree principal on September 30, 2026, releasing the related liens and ending the senior secured credit agreement, according to the SEC filing. The repayment is the latest balance-sheet event for the biotechnology company and gives its next earnings update a cleaner capital structure to explain.

Three dated capital steps

On July 27, 2026, Fortress Biotech announced a USD 130.00 million Series B financing for Crystalys Therapeutics, according to Fortress Biotech. On August 13, 2026, the company reported second-quarter revenue of USD 18.72 million, which BusinessQuant said was 7.20 percent above the USD 17.46 million consensus estimate, according to BusinessQuant. The September 30, 2026 repayment then removed the remaining USD 15.00 million principal and terminated the Oaktree agreement, the SEC reported in its October 1, 2026 filing.

What the repayment means for liquidity

Fortress Biotech had USD 196.6 million of cash at June 30, 2026, based on its second-quarter financial statements. Against that backdrop, the debt retirement removes a secured claim and related interest obligations, while the latest quarter also showed a USD 2.50 million consolidated net loss and diluted earnings per share of minus USD 0.08.

Next reporting date arrives in November

The next scheduled earnings report is November 12, 2026, according to StockIQ. The date matters because investors will have to weigh recurring product revenue against the cash use shown in operating activities during the second quarter, when operating cash flow was negative USD 59.3 million.

Market value after the debt payment

Fortress Biotech had a market capitalization of USD 64.8 million as of October 13, 2026, with a 52-week range of USD 1.93 to USD 4.53. The company is listed on the Nasdaq Capital Market under ticker FBIO and operates in the Healthcare sector and Biotechnology industry.

Market context: Market report Nasdaq Composite.